Jazz Pharmaceuticals signs a deal with Immunogen to develop and commercialize ADCs

Ireland-based biopharmaceutical company Jazz Pharmaceuticals is planning to team up with ImmunoGen Inc., one of the many pharma giants reputed for the development of antibody-drug conjugate therapeutics. Jazz is planning to invest USD 175 million in totality to sign the antibody pact with ImmunoGen. Through this deal, Jazz will acquire exclusive rights of two hematology antibody-drug conjugates (ADCs), while the third conjugate is yet to decided.

Under the terms and conditions of this agreement, ImmunoGen is solely responsible for the development of all three ADCs, if Jazz does not decide to take over the program. If it does so, then it will be responsible for further development, commercialization, and regulatory submissions of the ADCs program.

ImmunoGen is likely to strengthen its financial coffers post the closure of this deal. Jazz is paying around USD 75 million as an upfront payment to this biotechnology company. The remaining amount of USD 100 million, will be invested by Jazz in research and development activities for the next seven years. Presuming that other pharma giants may invest such potentially huge amounts in the development of antibody-drug conjugates (ADCs), it is estimated that the product portfolio of these companies may witness a slew of changes, thereby propelling the overall pharmaceutical market to some extent.

Under this agreement, once Jazz elects to opt in, it has to pay some amount for each program and the royalties based on the commercial sales of the product to ImmunoGen. This agreement covers following Immunogen program:

  • IMGN779, which is CD33 targeted ADC mainly used for the treatment of acute myeloid leukemia in phase one testing.
  • IMGN632, which is a CD123 ADC applicable for hematological malignancies.

Apart from the development of IMGN779 and IMGN632, both the organizations are willing to focus on the research of combination treatments for poor-prognosis acute myeloid leukemia, which is one of the innovative drugs of Jazz. As Vyxoes (daunorubicin and cytarabine) has been approved to treat AML, this deal is likely to fulfill the unmet needs of the hematology & oncology communities.

This strategic collaboration encompassing co-development and co-commercialization is likely to enhance the capability of both the organizations over the coming years. This collaboration may lead ImmunoGen to witness a stepwise development graph. In the first step, the company aims to accelerate its development in oncology and hematology assets. Later it may strengthen its balance sheet to support its lead program. Finally, the firm’s experts may analyze the study report related to Vyxeos. This, in turn, is predicted to become fruitful for this biotechnology company to substantially improve its product portfolio.

About Author

Sunil Hebbalkar

Sunil develops content for Market Size Forecasters. A Post graduate mechanical design engineer by qualification, he worked as an intern at the defense lab for one year in the engine design and development department before switching his professional genre. Following his technical writing skills, he ...

Read More